[The present status of the question of the mechanism of action of sulfanilamide hypoglycemic preparations and several aspects of their use in the treatment of diabetes mellitus].
D000818:Animals; D001786:Blood Glucose; D002271:Carbutamide / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003964:Diaphragm / Q000378:metabolism; D004285:Dogs; D004357:Drug Synergism; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014044:Tolbutamide / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D008112:Liver Glycogen; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D002271:Carbutamide; D005952:Glucose-6-Phosphatase; D005947:Glucose
Sovremennoe sostoianie voprosa o mekhanizme deĭstviia sul'fanilamidnykh gipoglikemiziruiushchikh preparatov i nekotorye aspekty ikh primeneniia pri lechenii sakharnogo diabeta.